IV Lacosamide: The Safety of Intravenous Lacosamide

Completed · Phase 3

Conditions studied: Epilepsy

In brief

The purpose of this study is to evaluate the safety of IV Lacosamide in children ages 4-35.

Key facts

Study ID

NCT01981447

Run by

Le Bonheur Children's Hospital

People needed

40

Starts

2010-04-01

Expected to finish

2012-08-01

Last updated by the study team

2020-09-22

Who can join

Age: 4 and older, up to 35. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patient or LAR must sign informed consent
• Diagnosis of partial onset currently uncontrolled
• Patient must have received anti-epileptic drug therapy prior to initiation
• Patient must have a medical condition in which parental administration is desireable
• Male or female
• Ages 4-35

You may not qualify if…

• Patient has participated in a study involving IV Lacosamide
• Patient has had an episode of status epilepticus in the last 3 months
• Drug history to lacosamide pregnant or lactating
• If of child bearing age, must have pregnancy test
• Patient has participated in an experimental drug study in last 30 days
• Patients with significant active hepatic or renal disease.
• Patients with known cardiac disease.

Where it is running

• Lebonheur Children's Hospital — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.